A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-α and interferon-γ inflammatory effects in human endothelial cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 4, 2008, Pages 718-724

  Lombardi, Adriana ^a   Cantini, Giulia ^a   Piscitelli, Elisabetta ^a   Gelmini, Stefania ^a   Francalanci, Michela ^a   Mello, Tommaso ^a   Ceni, Elisabetta ^a   Varano, Gabriele ^a   Forti, Gianni ^a   Rotondi, Mario ^a,b   Galli, Andrea ^a   Serio, Mario ^a   Luconi, Michaela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b IRCCS   (Italy)

Author keywords

CXCL10; Endothelium; MAPK; Th1 response; Thiazolidinediones

Indexed keywords

CELL ADHESION MOLECULE; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ROSIGLITAZONE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; CXCL10 PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TH1 CELL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; BIOSYNTHESIS; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS; CELL LINE; CHEMOKINE CXCL10; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INTERFERON TYPE II; MAP KINASE SIGNALING SYSTEM; PPAR GAMMA; SIGNAL TRANSDUCTION; TH1 CELLS; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42249089079     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.160713     Document Type: Article

References (39)

1. Rotondi M, Chiovato L, Romagnani S, Serio M, and Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007;28:492-520.
2. Ohmori Y, Hamilton TA. The interferon-stimulated response element and a κB site mediate synergistic induction of murine IP-10 gene transcription by IFN-γ and TNF-α. J Immunol. 1995;154:5235-5244.
3. Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A, Chieppa M, Allavena P, Ruco L, Girolomoni G, Sinigaglia F, Vecchi A, Mantovani A. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest. 2001;107:1173-1181.
4. Campbell IW. The clinical significance of PPAR γ agonism. Curr Mol Med. 2005;5:349-363.
5. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol. 2006;45:19-28.
6. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest. 1999;104:383-389.
7. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
8. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
9. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD. Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000;164:6503-6508.
10. Ricote M, Glass CK. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta. 2007;1771:926-935.
11. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, Tomas E. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab. 2006;291:E175-E181.
12. Konrad D, Rudich A, Bilan PJ, Patel N, Richardson C, Witters LA, Klip A. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia. 2005;48:954-966.
13. Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhausl W, Furnsinn C. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-γ-mediated changes in gene expression. Diabetes. 2001;50:2309-2315.
14. Castrillo A, Mojena M, Hortelano S, Bosca L. Peroxisome proliferatoractivated receptor-γ-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796,449. Comparison with the effects of 15-deoxy-δ(12,14)-prostaglandin J(2). J Biol Chem. 2001;276:34082-34088.
15. Chen L, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA. Peroxisome proliferator-activated receptor γ promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2. J Biol Chem. 2006;281:24575-24587.
16. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol. 2002;20:55-72.
17. Han J, Hajjar DP, Tauras JM, Feng J, Gotto AM Jr, Nicholson AC. Transforming growth factor-β1 (TGF-β1) and TGF-β-2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ. J Biol Chem. 2000;275:1241-1246.
18. Burgermeister E, Chuderl D, Hanoch T, Meyer M, Liscovitch M, Seger R. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor γ. Mol Cell Biol. 2007;27:803-817.
19. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 1993;11:767-804.
20. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24:34-40.
21. Wong CK, Tsang CM, Ip WK, Lam CW. Molecular mechanisms for the release of chemokines from human leukemic mast cell line (HMC)-1 cells activated by SCF and TNF-α: roles of ERK, p38 MAPK, and NF-κB. Allergy. 2006;61:289-297.
22. Kanda N, Watanabe S. Histamine inhibits the production of interferon-induced protein of 10 kDa in human squamous cell carcinoma and melanoma. J Invest Dermatol. 2002;119:1411-1419.
23. Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P. Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action? J Clin Endocrinol Metab. 2001;86:3250-3256.
24. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89:2728-2735.
25. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Haring HU, Koenig W, Marx N. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol. 2005;25:1804-1809.
26. Von Knethen A, Soller M, Tzieply N, Weigert A, Johann AM, Jennewein C, Kohl R, Brune B. PPARγ1 attenuates cytosol to membrane translocation of PKCα to desensitize monocytes/macrophages. J Cell Biol. 2007;176:681-694.
27. Bai YP, Liu YH, Chen J, Song T, You Y, Tang ZY, Li YJ, Zhang GG. Rosiglitazone attenuates NF-κB-dependent ICAM-1 and TNF-α production caused by homocysteine via inhibiting ERK(1/2)/p38MAPK activation. Biochem Biophys Res Commun. 2007;360:20-26.
28. Lee SJ, Namkoong S, Kim YM, Kim CK, Lee H, Ha KS, Chung HT, Kwon YG, Kim YM. Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol. 2006;291:H2836-H2846.
29. Robinson LA, Nataraj C, Thomas DW, Howell DN, Griffiths R, Bautch V, Patel DD, Feng L, Coffman TM. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol. 2000;165:6067-6072.
30. Lazzeri E, Rotondi M, Mazzinghi B, Lasagni L, Buonamano A, Rosati A, Pradella F, Fossombroni V, La Villa G, Gacci M, Bertoni E, Serio M, Salvadori M, Romagnani P. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation. 2005;79:1215-1220.
31. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, Smiley ST, Ling M, Gerard NP, Gerard C. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med. 2000;192:1515-1520.
32. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med. 2001;193:975-980.
33. Haskell CA, Hancock WW, Salant DJ, Gao W, Csizmadia V, Peters W, Faia K, Fituri O, Rottman JB, Charo IF. Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest. 2001;108:679-688.
34. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Possible relations between thyroid function, endothelium, and kidney and liver function in kidney allograft recipients. Transplant Proc. 2006;38:3509-3513.
35. Weis M, Cooke JP. Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway. Arterioscler Thromb Vasc Biol. 2003;23:567-575.
36. Van Loosdregt J, van Oosterhout MF, Bruggink AH, van Wichen DF, van Kuik J, de Koning E, Baan CC, de Jonge N, Gmelig-Meyling FH, de Weger RA. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation. 2006;114:1599-1607.
37. Kosuge H, Haraguchi G, Koga N, Maejima Y, Suzuki J, Isobe M. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation. 2006;113:2613-2622.
38. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
39. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med. 2007;357:28-38.